To include your compound in the COVID-19 Resource Center, submit it here.

Fragile X connection

Why Seaside, Roche partnered on mGluR5 and GABA B programs for fragile X

Last week's deal between Seaside Therapeutics Inc. and Roche has a slew of moving parts, with a different driver for each party. The key for the biotech was granting Roche an option to its lead fragile X syndrome program, which could allow Seaside to leverage the pharma's commercial muscle. Meanwhile, the pharma gains freedom to operate in the mGluR5 antagonist space, both in terms of IP and running clinical trials.

Fragile X syndrome is the most common known genetic form of autism. It is characterized by

Read the full 858 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers